Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis

Liver Transplantation

Volumn 15, Issue 12, 2009, Pages 1843-1851

  Malik, Shahid M ^a   DeVera, Michael E ^a   Fontes, Paulo ^a   Shaikh, Obaid ^a   Sasatomi, Eizaburo ^a   Ahmad, Jawad ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; STEROID;

ACUTE GRAFT REJECTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTATIC HEPATITIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 71249126103     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21943     Document Type: Article

References (43)

1. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16. (Pubitemid 46829973)
2. Browning JS, Szcepaniak LS, Dobbin LS, Nuremberg R, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
3. Bedogni G, Miglioli L, Masutti F, Tiribelli C. Prevalence and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
4. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007;13: 975-983. (Pubitemid 47163189)
5. Burke GW, Cirocco R, Hensley G, Ranjan D, Reddy R, Jeffers L, et al. Liver transplantation for cirrhosis following jejuno-ileal bypass-regional cytokine differences associated with pathological changes in the transplant liver. Transplantation 1992;54:374-377.
6. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62:1802-1805. (Pubitemid 27014542)
7. Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997;3:174-176. (Pubitemid 27114030)
8. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997;3:683.
9. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373. (Pubitemid 32331542)
10. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001;71:892-895. (Pubitemid 32417349)
11. Charlton M, Kasparava P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001;7:608-614. (Pubitemid 32677885)
12. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7:797-801. (Pubitemid 32851301)
13. Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Cryptogenic cirrhosis: clinicopathological findings at and after liver transplantation. Hum Pathol 2002;33:1098-1104. (Pubitemid 35416707)
14. Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnaravan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc 2003;35:2977-2980. (Pubitemid 38102106)
15. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669. (Pubitemid 29109578)
16. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-1219.
17. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2:1048-1058. (Pubitemid 40037633)
18. Brunt, EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16.
19. Malik SM, deVera M, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009;9:782-793.
20. Diehl AM, Goodman Z, Ishak KG. Alcohol like liver disease in nonalcoholics. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology 1988; 95:1056-1062.
21. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007;102:399-408. (Pubitemid 46160554)
22. Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, de Vera ME, et al. Liver biopsy findings from potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009;50: 501-510.
23. Laurel RF, Henley KS, Lucy MR. Acute cellular rejection after liver transplantation: variability, morbidity and mortality. Liver Transpl 2005;15:10-15.
24. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998;28:638-645. (Pubitemid 28405409)
25. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998;29:143-150.
26. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896. (Pubitemid 34267271)
27. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Kremers WK, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008;8:242-1233
28. Roche B, Samuel D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. J Hepatol 2003;39:S181-S189. (Pubitemid 37222670)
29. Jacob DA, Neumann UP, Bahra M, Klupp J, Puhl G, Neuhaus R, et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006;20:211-220.
30. Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes biochemical recurrence. Gut 2003;52: 893-897. (Pubitemid 36613499)
31. Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18:62-69. (Pubitemid 38195546)
32. Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008;14:245-251. (Pubitemid 351267284)
33. Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004;99:538-542. (Pubitemid 38524137)
34. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001;27:619-626. (Pubitemid 32802742)
35. Cuadrado A, Fabrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 2005;11:420-426. (Pubitemid 40533210)
36. Marsh JW, Dvorchik I, Subotin M, Balan V, Rakela J, Popechitelev EP, at al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology 1997;26:444-450.
37. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carci- noma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540. (Pubitemid 38443593)
38. Island ER, Pomposelli J, Pomfret EA, Gordon DF, Lewis DW, Jenkins RL. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 2005; 140:353-358. (Pubitemid 40489952)
39. Zavaglia C, DeCarlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005;100:2708-2716. (Pubitemid 43919639)
40. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam, R, et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008;14:956-965. (Pubitemid 352003894)
41. Abdurrahman K, Raphael B, Merriman MB, Bass NM. Medical treatment for non-alcoholic steatohepatitis. Clin Liver Dis 2007;11:119-140.
42. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307. (Pubitemid 44837778)
43. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.